CClinicalTrials.gg
CompletedNCT07553130Updated Apr 27, 2026

AcceXible Speech-Based Screening for Depression and Anxiety in University Students (BUAP, Mexico)

An observational study in Depression - Major Depressive Disorder and Anxiety, sponsored by Accexible. Completed at 1 site in Mexico. Open to participants aged 16 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Accexible · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
785
Ages
16 Years to 25 Years
Sex
All
01

Study summary

Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD). Emerging evidence suggests that depression affects both the acoustic properties and content of speech, making speech analysis a promising candidate as a digital biomarker for early screening.

This study evaluates the validity of acceXible, a speech-based machine learning platform, for the detection and monitoring of depression and anxiety in the student population of the Benemérita Universidad Autónoma de Puebla (BUAP), Mexico. AcceXible captures spontaneous speech through open-ended interview tasks and applies automated acoustic and linguistic analysis.

The primary objective is to evaluate the validity of the acceXible spontaneous speech analysis system for depression and anxiety screening, assessed against the PHQ and GAD scales as reference standards. Secondary objectives include examining associations between speech-derived variables and other study measures, evaluating participant engagement with digital mental health resources, assessing user satisfaction with the platform, and analyzing longitudinal changes in scores across follow-up assessments.

02

Conditions studied

  • Depression - Major Depressive Disorder
  • Anxiety

Keywords

  • machine learning
  • depression
  • anxiety
  • Accexible
  • screening
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 785 is above the median of 150 across 606 observational studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Accexible is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

University students enrolled at the Benemérita Universidad Autónoma de Puebla (BUAP), Puebla, Mexico.

Inclusion criteria

  • Provision of voluntary written informed consent
  • Age 16-25 years
  • Current enrollment at BUAP
  • Spanish language proficiency
  • Access to a mobile device with internet connectivity
  • Ability to understand and follow basic acceXible usage instructions

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • Psychomotor agitation
  • Sensory impairment (visual or auditory)
  • Cognitive impairment
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
785 participants (actual)
Patient registry
No

Interventions

  • DeviceAcceXible

    Speech analysis

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of acceXible for depression and anxiety screening

    Sensitivity, specificity, and positive predictive value of the acceXible speech analysis system relative to validated Spanish-language versions of the PHQ-9 and GAD-7 as reference standards. Sensitivity is defined as the probability of correctly classifying a participant with abnormal scores; specificity as the probability of correctly classifying a non-affected participant; and positive predictive value as the probability that a participant flagged by acceXible truly meets criteria for depression or anxiety.

    Time frame: Baseline

07

Study locations

1 site
  • Benemérita Universidad Autónoma de Puebla
    Puebla City, 72570, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07553130
Lead sponsor
Accexible
Collaborators
Benemerita Universidad Autónoma de Puebla
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
Nov 20, 2024
Primary completion
Jun 6, 2025
Completion
Jun 6, 2025
Last update
Apr 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion